Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial
- Author
- WRESSNIGG, Nina1 ; PÖLLABAUER, Eva-Maria1 ; PILZ, Andreas3 ; DVORAK, Thomas2 ; SINGER, Julia2 ; FIRTH, Clair2 ; LUFT, Benjamin4 ; SCHMITT, Bernhard5 ; ZEITLINGER, Markus6 ; MÜLLER, Markus6 ; KOLLARITSCH, Herwig6 ; PAULKE-KORINEK, Maria6 ; AICHINGER, Gerald1 ; ESEN, Meral7 ; KREMSNER, Peter G7 ; EHRLICH, Hartmut J2 ; BARRETT, P. Noel3 ; PORTSMOUTH, Daniel3 ; LÖW-BASELLI, Alexandra1 ; FRITSCH, Sandor2 ; LIVEY, Ian3 ; CROWE, Brian A3 ; SCHWENDINGER, Michael3 ; BRÜHL, Peter3
[1] Vaccine R&D, Baxter BioScience, Vienna, Austria
[2] Global R&D, Baxter BioScience, Vienna, Austria
[3] Vaccine R&D, Baxter Bioscience, Orth an der Donau, Austria
[4] Stony Brook University Medical Center, Stony Brook, NY, United States
[5] Health Center Mainz, Mainz, Germany
[6] Medical University of Vienna, Vienna, Austria
[7] Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany - Source
Lancet. Infectious diseases (print). 2013, Vol 13, Num 8, pp 680-689, 10 p ; ref : 42 ref
- ISSN
- 1473-3099
- Scientific domain
- General medicine general surgery; Microbiology, infectious diseases
- Publisher
- Lancet Publishing Group, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Adulte Dose Immunogénicité Immunoprophylaxie Maladie de Lyme Prévention Vaccin Bactériose Borréliose Homme Infection Spirochétose
- Keyword (en)
- Adult Dose Immunogenicity Immunoprophylaxis Lyme disease Prevention Vaccine Bacteriosis Borrelia infection Human Infection Spirochaetosis
- Keyword (es)
- Adulto Dosis Inmunogenicidad Inmunoprofilaxia Artritis inflamatoria epidémica Prevención Vacuna Bacteriosis Borreliosis Hombre Infección Espiroquetosis
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05B Bacterial diseases / 002B05B02 Human bacterial diseases / 002B05B02L Tropical bacterial diseases / 002B05B02L6 Borrelia infections
- Discipline
- Infectious pathology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27567068
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S1473-3099(13)70110-5 
https://dx.doi.org/10.1016/S1473-3099(13)70110-5
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70110-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:165:\"Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:3:\"680\";s:8:\"\u0000*\u0000epage\";s:3:\"689\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"WRESSNIGG\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Nina\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:22:\"P\u00d6LLABAUER, Eva-Maria\";i:1;s:13:\"PILZ, Andreas\";i:2;s:14:\"DVORAK, Thomas\";i:3;s:13:\"SINGER, Julia\";i:4;s:12:\"FIRTH, Clair\";i:5;s:14:\"LUFT, Benjamin\";i:6;s:17:\"SCHMITT, Bernhard\";i:7;s:18:\"ZEITLINGER, Markus\";i:8;s:15:\"M\u00dcLLER, Markus\";i:9;s:19:\"KOLLARITSCH, Herwig\";i:10;s:21:\"PAULKE-KORINEK, Maria\";i:11;s:17:\"AICHINGER, Gerald\";i:12;s:11:\"ESEN, Meral\";i:13;s:17:\"KREMSNER, Peter G\";i:14;s:18:\"EHRLICH, Hartmut J\";i:15;s:16:\"BARRETT, P. Noel\";i:16;s:18:\"PORTSMOUTH, Daniel\";i:17;s:23:\"L\u00d6W-BASELLI, Alexandra\";i:18;s:15:\"FRITSCH, Sandor\";i:19;s:10:\"LIVEY, Ian\";i:20;s:14:\"CROWE, Brian A\";i:21;s:21:\"SCHWENDINGER, Michael\";i:22;s:13:\"BR\u00dcHL, Peter\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:165:\"Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70110-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:165:\"Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:3:\"680\";s:8:\"\u0000*\u0000epage\";s:3:\"689\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"WRESSNIGG\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Nina\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:22:\"P\u00d6LLABAUER, Eva-Maria\";i:1;s:13:\"PILZ, Andreas\";i:2;s:14:\"DVORAK, Thomas\";i:3;s:13:\"SINGER, Julia\";i:4;s:12:\"FIRTH, Clair\";i:5;s:14:\"LUFT, Benjamin\";i:6;s:17:\"SCHMITT, Bernhard\";i:7;s:18:\"ZEITLINGER, Markus\";i:8;s:15:\"M\u00dcLLER, Markus\";i:9;s:19:\"KOLLARITSCH, Herwig\";i:10;s:21:\"PAULKE-KORINEK, Maria\";i:11;s:17:\"AICHINGER, Gerald\";i:12;s:11:\"ESEN, Meral\";i:13;s:17:\"KREMSNER, Peter G\";i:14;s:18:\"EHRLICH, Hartmut J\";i:15;s:16:\"BARRETT, P. Noel\";i:16;s:18:\"PORTSMOUTH, Daniel\";i:17;s:23:\"L\u00d6W-BASELLI, Alexandra\";i:18;s:15:\"FRITSCH, Sandor\";i:19;s:10:\"LIVEY, Ian\";i:20;s:14:\"CROWE, Brian A\";i:21;s:21:\"SCHWENDINGER, Michael\";i:22;s:13:\"BR\u00dcHL, Peter\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:165:\"Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70110-5\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70110-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:165:\"Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:3:\"680\";s:8:\"\u0000*\u0000epage\";s:3:\"689\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"WRESSNIGG\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Nina\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:22:\"P\u00d6LLABAUER, Eva-Maria\";i:1;s:13:\"PILZ, Andreas\";i:2;s:14:\"DVORAK, Thomas\";i:3;s:13:\"SINGER, Julia\";i:4;s:12:\"FIRTH, Clair\";i:5;s:14:\"LUFT, Benjamin\";i:6;s:17:\"SCHMITT, Bernhard\";i:7;s:18:\"ZEITLINGER, Markus\";i:8;s:15:\"M\u00dcLLER, Markus\";i:9;s:19:\"KOLLARITSCH, Herwig\";i:10;s:21:\"PAULKE-KORINEK, Maria\";i:11;s:17:\"AICHINGER, Gerald\";i:12;s:11:\"ESEN, Meral\";i:13;s:17:\"KREMSNER, Peter G\";i:14;s:18:\"EHRLICH, Hartmut J\";i:15;s:16:\"BARRETT, P. Noel\";i:16;s:18:\"PORTSMOUTH, Daniel\";i:17;s:23:\"L\u00d6W-BASELLI, Alexandra\";i:18;s:15:\"FRITSCH, Sandor\";i:19;s:10:\"LIVEY, Ian\";i:20;s:14:\"CROWE, Brian A\";i:21;s:21:\"SCHWENDINGER, Michael\";i:22;s:13:\"BR\u00dcHL, Peter\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:165:\"Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70110-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:165:\"Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:3:\"680\";s:8:\"\u0000*\u0000epage\";s:3:\"689\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"WRESSNIGG\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Nina\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:22:\"P\u00d6LLABAUER, Eva-Maria\";i:1;s:13:\"PILZ, Andreas\";i:2;s:14:\"DVORAK, Thomas\";i:3;s:13:\"SINGER, Julia\";i:4;s:12:\"FIRTH, Clair\";i:5;s:14:\"LUFT, Benjamin\";i:6;s:17:\"SCHMITT, Bernhard\";i:7;s:18:\"ZEITLINGER, Markus\";i:8;s:15:\"M\u00dcLLER, Markus\";i:9;s:19:\"KOLLARITSCH, Herwig\";i:10;s:21:\"PAULKE-KORINEK, Maria\";i:11;s:17:\"AICHINGER, Gerald\";i:12;s:11:\"ESEN, Meral\";i:13;s:17:\"KREMSNER, Peter G\";i:14;s:18:\"EHRLICH, Hartmut J\";i:15;s:16:\"BARRETT, P. Noel\";i:16;s:18:\"PORTSMOUTH, Daniel\";i:17;s:23:\"L\u00d6W-BASELLI, Alexandra\";i:18;s:15:\"FRITSCH, Sandor\";i:19;s:10:\"LIVEY, Ian\";i:20;s:14:\"CROWE, Brian A\";i:21;s:21:\"SCHWENDINGER, Michael\";i:22;s:13:\"BR\u00dcHL, Peter\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:165:\"Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70110-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:165:\"Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:3:\"680\";s:8:\"\u0000*\u0000epage\";s:3:\"689\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"WRESSNIGG\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Nina\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:22:\"P\u00d6LLABAUER, Eva-Maria\";i:1;s:13:\"PILZ, Andreas\";i:2;s:14:\"DVORAK, Thomas\";i:3;s:13:\"SINGER, Julia\";i:4;s:12:\"FIRTH, Clair\";i:5;s:14:\"LUFT, Benjamin\";i:6;s:17:\"SCHMITT, Bernhard\";i:7;s:18:\"ZEITLINGER, Markus\";i:8;s:15:\"M\u00dcLLER, Markus\";i:9;s:19:\"KOLLARITSCH, Herwig\";i:10;s:21:\"PAULKE-KORINEK, Maria\";i:11;s:17:\"AICHINGER, Gerald\";i:12;s:11:\"ESEN, Meral\";i:13;s:17:\"KREMSNER, Peter G\";i:14;s:18:\"EHRLICH, Hartmut J\";i:15;s:16:\"BARRETT, P. Noel\";i:16;s:18:\"PORTSMOUTH, Daniel\";i:17;s:23:\"L\u00d6W-BASELLI, Alexandra\";i:18;s:15:\"FRITSCH, Sandor\";i:19;s:10:\"LIVEY, Ian\";i:20;s:14:\"CROWE, Brian A\";i:21;s:21:\"SCHWENDINGER, Michael\";i:22;s:13:\"BR\u00dcHL, Peter\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:165:\"Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
